Form 4: Labcorp EVP earns 6,604 shares; 2,879 withheld

EVP and CHRO Anita Z. Graham acquired 6,604 Labcorp shares from a vested performance award and had 2,879 shares withheld for taxes, leaving 5,185 shares owned.

Summary

• On 03/26/2026, EVP and CHRO Anita Z. Graham acquired 6,604 shares of Labcorp common stock at $0 pursuant to a performance award granted on 04/05/2023 for the three-year period ending 12/31/2025.
• On the same date, 2,879 shares were withheld (Code F) to satisfy tax obligations at a price of $268.38 per share.
• Beneficial ownership increased to 8,064 shares after the award vested and stood at 5,185 shares after tax withholding.
• Implied net increase in beneficial ownership is 3,725 shares (from approximately 1,460 before the award to 5,185 after withholding).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as modestly positive due to performance award vesting and a net increase in insider ownership, with no discretionary selling beyond tax withholding.

Positives

• Performance-based award vested for the 2023–2025 period, indicating achievement of set performance criteria.
• Net increase in executive share ownership by 3,725 shares, enhancing alignment with shareholders.
• No open-market sale; the only disposition (2,879 shares) was for tax withholding purposes.

Negatives

• 2,879 shares were disposed to cover tax withholding at $268.38 per share.

Future Outlook

No forward-looking statements or guidance provided.

Industry Context

StockSavvy.ai notes that performance-based long-term incentive vesting with concurrent tax withholding is standard practice across large-cap U.S. healthcare companies; such insider updates typically carry limited near-term share price impact.

Comparison to Industry Standards

• Tax-withholding dispositions (Form 4 Code F) are common among peers such as Quest Diagnostics (DGX), HCA Healthcare (HCA), and Danaher (DHR), and generally do not signal discretionary selling.
• Three-year performance cycles for executive LTIs (e.g., 2023–2025) align with sector norms emphasizing TSR and financial KPIs.
• A net increase in insider ownership following award vesting aligns with governance best practices that promote executive-shareholder alignment.

Stakeholder Impact

• Executive equity award vesting may signal achievement of multi-year performance goals.
• No open-market selling; shares were withheld solely to cover taxes.
• Post-transaction executive beneficial ownership is 5,185 shares.

Key Dates

Keywords

Labcorp, LH, insider transaction, Form 4, Anita Z. Graham, executive compensation, performance award, stock withholding, beneficial ownership, healthcare diagnostics